No Data
Shanghai Kaibao Pharmaceutical (300039.SZ): Currently, the company has no weight-loss related products.
Gelonghui reported on April 21 that Shanghai Kaibao Pharmaceutical (300039.SZ) stated on the interactive platform that the company currently has no related weight loss products. The company and its subsidiaries hold product licenses for pediatric cough and asthma oral solution, pediatric cough and asthma granules, pediatric fever-reducing oral solution, pediatric gastric tonic syrup, pediatric compound sulfamethoxazole tablets, and pediatric pharyngeal granules, among others. The pediatric pharyngeal granules, a product of Xinyi Pharmaceutical, are already on the market and can be purchased at grassroots community clinics, pharmacies, and online at JD.com, while the other products are not yet in production.
Shanghai Kaibao: Report for the first quarter of 2025
Shanghai Kaibao: 2024 Annual Report
Shanghai Kaibao: 2024 Annual Report Summary
Shanghai Kaibao Pharmaceutical (300039.SZ): The Net income for the fiscal year 2024 is 0.376 billion yuan, with a proposed distribution of 1 yuan per share.
Gelonghui, on April 15, announced that Shanghai Kaibao Pharmaceutical (300039.SZ) published its annual report for 2024. In 2024, the company achieved a revenue of 1.473 billion yuan, a year-on-year decrease of 7.57%; the Net income attributable to shareholders of the listed company was 0.376 billion yuan, an increase of 14.55% year-on-year; the Net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 0.353 billion yuan, a year-on-year increase of 21.16%; the EPS was 0.3591 yuan; it is proposed to distribute a cash dividend of 1.00 yuan (including tax) for every 10 shares to all shareholders.
Shanghai Kaibao Pharmaceutical (300039.SZ) announced its first-quarter performance, with a net income of 84.2928 million yuan, a decrease of 4.71%.
Shanghai Kaibao Pharmaceutical (300039.SZ) released its first quarter report for 2025, with revenue of 4.01...
The Market Doesn't Like What It Sees From Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Earnings Yet
